Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

2.705 -0.355 (-11.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,411
Open 2.910
Bid (Size) 2.700 (1)
Ask (Size) 2.800 (1)
Prev. Close 3.060
Today's Range 2.600 - 3.041
52wk Range 2.350 - 7.260
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga

Performance

YTD
-11.89%
-11.89%
1 Month
-11.89%
-11.89%
3 Month
-30.66%
-30.66%
6 Month
-46.96%
-46.96%
1 Year
-46.96%
-46.96%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Stock Surges After Positive Study Results From Arthritis Study
Via Benzinga
Silo Pharma Announces Expansion of Intellectual Property Portfolio
From Silo Pharma, Inc.
Via Globe NewsWire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program
Via Investor Brand Network
Silo Pharma Announces Stock Repurchase Program
From Silo Pharma, Inc.
Via Globe NewsWire
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide
Via Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis
Via Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Clinical Study Examining Psilocybin’s Effect on Inflammation
Via Investor Brand Network
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
From Silo Pharma, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study
Via Investor Brand Network
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
Via Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq Falls 100 Points; Dermata Therapeutics Shares Surge
Via Benzinga
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
Via Spotlight Growth
US Stocks Open Lower; Dow Drops 250 Points
Via Benzinga
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
Via FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.